{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:54:14Z","timestamp":1794110054066,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373739"],"award-info":[{"award-number":["82373739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007820","name":"Hangzhou Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022977","name":"Frontiers Science Center for Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118578","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:57:19Z","timestamp":1768291039000},"page":"118578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Rational design of an NLRP3 inhibitor with superior efficacy and safety for gout therapy"],"prefix":"10.1016","volume":"305","author":[{"given":"Yichao","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-3864","authenticated-orcid":false,"given":"Lei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiabin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118578_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2026.118578_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110466","article-title":"Immune and inflammatory mechanisms and therapeutic targets of gout: an update","volume":"121","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.118578_bib3","article-title":"Role of NLRP3 in the pathogenesis and treatment of gout arthritis","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118578_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","article-title":"Uric acid as a danger signal in gout and its comorbidities","volume":"9","author":"Rock","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118578_bib5","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s10067-021-05595-w","article-title":"Comorbidities and factors influencing frequent gout attacks in patients with gout: a cross-sectional study","volume":"40","author":"Liang","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118578_bib6","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejmech.2026.118578_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.118578_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113598","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs): a current insight into its molecular mechanism eliciting organ toxicities","volume":"172","author":"Panchal","year":"2023","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118578_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26061576","article-title":"Lipid formulations and bioconjugation strategies for indomethacin therapeutic advances","volume":"26","author":"Gliszczy\u0144ska","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118578_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mco2.69","article-title":"The emerging role of neutrophils in autoimmune-associated disorders: effector, predictor, and therapeutic targets","volume":"2","author":"Fu","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118578_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111932","article-title":"Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions","volume":"132","author":"Yang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2026.118578_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","article-title":"The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout","volume":"29","author":"Kim","year":"2022","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.ejmech.2026.118578_bib13","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-013-0361-0","article-title":"Neutrophils, IL-1\u03b2, and gout: is there a link?","volume":"35","author":"Mitroulis","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2026.118578_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164996","article-title":"Promise of the NLRP3 inflammasome inhibitors in in vivo disease models","volume":"26","author":"Das","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118578_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.634607","article-title":"NLRP3 inflammasome: a promising therapeutic target for drug-induced toxicity","volume":"9","author":"Wei","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2026.118578_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejmech.2026.118578_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118578_bib19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1021\/acs.jmedchem.5b01091","article-title":"Inhibiting the inflammasome: a chemical perspective","volume":"59","author":"Baldwin","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejmech.2026.118578_bib21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118578_bib22","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118578_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2026.118578_bib24","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118578_bib25","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/cmdc.201600055","article-title":"Design, synthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome inhibitors","volume":"11","author":"Cocco","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118578_bib26","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118578_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128693","article-title":"Design and synthesis of an N-benzyl 5-(4-sulfamoylbenzylidene-2-thioxothiazolidin-4-one scaffold as a novel NLRP3 inflammasome inhibitor","volume":"65","author":"Zuo","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2026.118578_bib28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of alzheimer's disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2026.118578_bib29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1189\/jlb.3A0114-005RR","article-title":"Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation","volume":"96","author":"Honda","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2026.118578_bib30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/acs.jmedchem.0c01924","article-title":"Development of novel tetrahydroquinoline inhibitors of NLRP3 inflammasome for potential treatment of DSS-induced mouse colitis","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/acsmedchemlett.3c00122","article-title":"1,2,4-Triazine derivatives as NLRP3 inhibitors for treating diseases","volume":"14","author":"Sabnis","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118578_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.1318","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of ZY-IL1 in three patients with cryopyrin-associated periodic syndromes","volume":"13","author":"Hissaria","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ejmech.2026.118578_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118578_bib34","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","article-title":"Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117874","article-title":"Recent advances in the treatment of gout with NLRP3 inflammasome inhibitors","volume":"112","author":"Tian","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118578_bib37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118578_bib38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118578_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118578_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121353119","article-title":"Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation","volume":"119","author":"Ohto","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118578_bib41","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41467-024-45396-8","article-title":"Structural basis for the oligomerization-facilitated NLRP3 activation","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118578_bib42","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118578_bib43","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1021\/acs.jmedchem.3c00894","article-title":"Novel sulfonylurea-based NLRP3 inflammasome inhibitor for efficient treatment of nonalcoholic steatohepatitis, endotoxic shock, and colitis","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/chin.200343088","article-title":"Novel synthesis of 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3- [4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an antiinflammatory agent","volume":"34","author":"Urban","year":"2003","journal-title":"ChemInform"},{"key":"10.1016\/j.ejmech.2026.118578_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejmech.2018.10.018","article-title":"Naphthalene, a versatile platform in medicinal chemistry: Sky-high perspective","volume":"161","author":"Makar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118578_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118578_bib47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.ejmech.2026.118578_bib48","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2026.118578_bib49","article-title":"Inflammatory response to regulated cell death in gout and its functional implications","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118578_bib50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1142\/S0129183110015919","article-title":"Solving the time-dependent SCHR\u00d6DINGER equation with absorbing boundary conditions and source terms in Mathematica 6.0","volume":"21","author":"Dubeibe","year":"2010","journal-title":"Int. J. Mod. Phys. C"},{"key":"10.1016\/j.ejmech.2026.118578_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"10.1016\/j.ejmech.2026.118578_bib52","doi-asserted-by":"crossref","first-page":"W665","DOI":"10.1093\/nar\/gkh381","article-title":"PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations","volume":"32","author":"Dolinsky","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118578_bib53","article-title":"Preparation and culture of bone marrow-derived macrophages from mice for functional analysis","volume":"2","author":"Toda","year":"2021","journal-title":"STAR Protoc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:06:34Z","timestamp":1773536794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0223523426000231"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118578","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of an NLRP3 inhibitor with superior efficacy and safety for gout therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118578"}}